betoptic s 25 mg ml eye drops suspension in single dose containe - Результаты поиска

novartis ireland limited vista building, elm park, merrion road, ballsbridge, dublin 4,, ireland - betaxolol hydrochloride - eye drops, suspension - betaxolol hydrochloride 2.5 mg/ml - ophthalmologicals

Соединенные Штаты - английский - NLM (National Library of Medicine)

betoptic s- betaxolol hydrochloride suspension/ drops

alcon laboratories, inc. - betaxolol hydrochloride (unii: 6x97d2xt0o) (betaxolol - unii:o0zr1r6rz2) - betaxolol hydrochloride 2.8 mg in 1 ml - betoptic s® (betaxolol hydrochloride ophthalmic suspension) 0.25% is indicated for the treatment of elevated intraocular pressure (iop) in patients with chronic open-angle glaucoma or ocular hypertension. betoptic s is contraindicated in patients with: - sinus bradycardia - greater than a first degree atrioventricular (av) block - cardiogenic shock - patients with overt cardiac failure - hypersensitivity to any component of this product risk summary there are no adequate and well-controlled studies of betoptic s administration in pregnant women to inform a drug-associated risk. there are limited data with the use of betaxolol eye drops in pregnant women. epidemiological studies have not revealed malformative effects but show a risk for intrauterine growth retardation when beta-blockers are administered by the oral route. in animal reproductive studies, no drug-induced maternal toxicity or teratogenicity was observed at clinically relevant doses (see data) . because animal reproductive studies are not always

Соединенные Штаты - английский - NLM (National Library of Medicine)

betoptic pilo- betaxolol hydrochloride and pilocarpine hydrochloride

alcon laboratories, inc. - betaxolol hydrochloride (unii: 6x97d2xt0o) (betaxolol - unii:o0zr1r6rz2) - kit - betoptic® pilo ophthalmic suspension is indicated for the reduction of elevated intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension who are insufficiently responsive to betoptic® -s (failed to achieve target iop determined after multiple measurements over time). it is not known whether betoptic® pilo is equivalent in iop lowering efficacy to the administration of betoptic® -s 0.25% and pilocarpine 1.75% dosed separately. it is not known whether betoptic® pilo is equivalent to other beta-blockers given in combination with pilocarpine. betoptic® pilo ophthalmic suspension is contraindicated in patients with sinus bradycardia, greater than a first degree atrioventricular heart block, cardiogenic shock or patients with overt cardiac failure. betoptic® pilo ophthalmic suspension is also contraindicated in conditions where miosis is undesirable (e.g., peripheral anterior synechia, trauma, acute inflammatory disease of the anterior chamber, glaucoma occurring or persisting